Keyword: Seattle Genetics
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.
The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. With Merck’s Keytruda, the med shrank 71% of bladder tumors, new data show.
The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.
Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.
Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.
The former VP of clinical development at cancer biotech Seattle Genetics has jumped ship to Zymeworks.
The trial linked the antibody-drug conjugate to a 44% response rate in patients with locally advanced or metastatic urothelial cancer.
Seattle Genetics names Keytruda developer as CMO and Aravive CEO Stephen Eck leaves to join Immatics.
Seattle Genetics appointed Roger Dansey as CMO, who led Merck’s late-stage oncology work, including developing Keytruda in multiple tumor types.
